Daiichi Sankyo

Historical price data

Daiichi Sankyo has successfully pivoted from a traditional pharmaceutical company to a global oncology leader, anchored by its groundbreaking DXd ADC technology platform. Its flagship drug, ENHERTU, developed in partnership with AstraZeneca, has achieved multi-billion dollar sales and is expanding into earlier lines of therapy across multiple HER2-expressing cancers. The company's strategy focuses on leveraging its platform to build a deep, diversified pipeline targeting HER2, TROP2, and other tumor antigens, aiming to become a world-leading oncology company by 2030.

Proprietary DXd antibody-drug conjugate (ADC) platform featuring a high drug-to-antibody ratio, stable cleavable tetrapeptide linker, and potent topoisomerase I inhibitor payload (DXd) with a bystander effect.